Related Experiment Video
Updated: Jan 7, 2026
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
Kolaviron attenuates Dextran sulphate sodium-induced colitis by enhancing the expression of MUC-2
Adeoti G Adeniran1, Blessing O Omolaso2, Motunrayo O Afuye1
1Department of Physiology, Faculty of Basic Medical Sciences, University of Medical Sciences, Ondo City, Ondo State, Nigeria.
Abstract:
Ulcerative colitis, a chronic inflammatory bowel disease, is a complex and multifactorial disease with unknown etiology that remains challenging in its management due to pathophysiological complexity and limited success with conventional therapies such as 5-aminosalicylic acid, corticosteroids, and anti-TNF-α antibodies. This study examines the therapeutic potential of Kolaviron, a biflavonoid complex from Garcinia kola, with a novel focus on its effect on colonic MUC-2 expression, a key component of the intestinal mucus barrier, together with its known antioxidant and anti-inflammatory actions in dextran sulphate sodium (DSS)-induced colitis in a Wistar rat model. Rats were randomly divided into 4 groups (n = 5 per group): Group 1 (Control) received vehicle (DMSO); Groups 2, 3, and 4 were administered 5% (w/v) DSS orally and received DMSO, kolaviron, or sulfasalazine (200 mg/kg), respectively. Kolaviron significantly reduced disease activity index, oxidative stress markers, myeloperoxidase activity, TNF-α, IL-6, and lipid peroxidation. It also improved colonic histoarchitecture and remarkably enhanced the expression of MUC-2. In silico docking analysis showed strong binding affinities of Kolaviron to NF-κB and phospholipase C, pointing to its contribution in the regulation of molecular pathways for MUC-2 expression. Kolaviron significantly reduced the disease activity index and colonic oxidative stress by enhancing antioxidant levels and decreasing myeloperoxidase activity, tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and lipid peroxidation, with the novel enhancement of MUC-2 expression, highlighting its potential role in restoring mucosal barrier integrity.
Insights
Kolaviron, a natural compound, shows promise in treating ulcerative colitis by reducing inflammation and enhancing the protective mucus layer (MUC-2). This study highlights its potential to restore gut barrier integrity in a rat model.
Area of Science:
- Gastroenterology
- Pharmacology
- Natural Product Research
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease with complex etiology and limited treatment options.
- Conventional therapies for UC often have insufficient efficacy or significant side effects.
- The intestinal mucus barrier, particularly MUC-2 expression, plays a crucial role in UC pathogenesis.
Purpose of the Study:
- To investigate the therapeutic potential of Kolaviron, a biflavonoid from Garcinia kola, in a dextran sulphate sodium (DSS)-induced ulcerative colitis rat model.
- To evaluate Kolaviron's effects on colonic MUC-2 expression, antioxidant activity, and inflammatory markers.
- To explore the molecular mechanisms underlying Kolaviron's action, including its interaction with NF-κB and phospholipase C.
Main Methods:
- Induction of colitis in Wistar rats using 5% DSS.
- Administration of Kolaviron or sulfasalazine (positive control) to DSS-treated rats.
- Assessment of disease activity index, oxidative stress markers, myeloperoxidase activity, inflammatory cytokines (TNF-α, IL-6), lipid peroxidation, and MUC-2 expression.
- In silico docking analysis to predict Kolaviron's molecular targets.
Main Results:
- Kolaviron significantly reduced the disease activity index and improved colonic histoarchitecture in DSS-induced colitis.
- Kolaviron demonstrated potent antioxidant effects, decreasing oxidative stress markers and lipid peroxidation.
- Kolaviron markedly enhanced MUC-2 expression, suggesting restoration of the intestinal mucus barrier, and showed strong binding affinities to NF-κB and phospholipase C.
Conclusions:
- Kolaviron exhibits significant therapeutic potential for ulcerative colitis by reducing inflammation and oxidative stress.
- Kolaviron's novel enhancement of MUC-2 expression is key to restoring mucosal barrier integrity.
- Kolaviron represents a promising natural compound for developing new strategies to manage ulcerative colitis.
More Related Videos
08:34Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...